S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
The 3-Stock Retirement Blueprint (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
The 3-Stock Retirement Blueprint (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
The 3-Stock Retirement Blueprint (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:KPTI

Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

$5.93
+0.05 (+0.85%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.76
$6.01
50-Day Range
$4.08
$5.93
52-Week Range
$4.00
$14.73
Volume
1.52 million shs
Average Volume
2.71 million shs
Market Capitalization
$473.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.88

Karyopharm Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
66.5% Upside
$9.88 Price Target
Short Interest
Healthy
19.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.82mentions of Karyopharm Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$59,992 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.07) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

184th out of 1,072 stocks

Pharmaceutical Preparations Industry

76th out of 534 stocks

KPTI stock logo

About Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

Karyopharm Therapeutics Inc. (KPTI)
Expert Ratings for Karyopharm Therapeutics
Karyopharm to Participate at Upcoming Investor Conferences
Why Karyopharm Therapeutics Inched Higher Today
Karyopharm director sells ~$3.4M in company shares
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
442
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.88
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+66.5%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-124,090,000.00
Pretax Margin
-41.11%

Debt

Sales & Book Value

Annual Sales
$209.82 million
Book Value
($1.05) per share

Miscellaneous

Free Float
71,635,000
Market Cap
$473.26 million
Optionable
Optionable
Beta
-0.08

Key Executives

  • Mr. Richard A. Paulson M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $1.27M
  • Dr. Sharon Shacham M.B.A. (Age 52)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
    Comp: $766.54k
  • Mr. Michael P. Mason CPAMr. Michael P. Mason CPA (Age 47)
    M.B.A., Exec. VP, CFO & Treasurer
    Comp: $692.39k
  • Mr. Ran Frenkel R.Ph. (Age 53)
    RPh, Global Head of Clinical Operations
    Comp: $667.87k
  • Dr. Mansoor Raza Mirza M.D. (Age 61)
    Clinical Consultant, Member of Scientific Advisory Board & Independent Director
    Comp: $146.14k
  • Mr. Cameron Peters (Age 62)
    VP of Fin., Assistant Treasurer & Principal Accounting Officer
  • Mr. Pierre S. Sayad M.S.
    Ph.D., VP of Global Medical & Scientific Affairs
  • Ms. Elhan Webb C.F.A.
    Sr. VP of Investor Relations
  • Mr. Michael J. Mano J.D. (Age 45)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Lisa Meletta J.D.
    VP of Legal & Chief Compliance Officer













KPTI Stock - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KPTI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View KPTI analyst ratings
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2022?

7 Wall Street research analysts have issued twelve-month price objectives for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $6.00 to $18.00. On average, they expect the company's stock price to reach $9.88 in the next year. This suggests a possible upside of 66.5% from the stock's current price.
View analysts price targets for KPTI
or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2022?

Karyopharm Therapeutics' stock was trading at $6.43 at the start of the year. Since then, KPTI stock has decreased by 7.8% and is now trading at $5.93.
View the best growth stocks for 2022 here
.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our KPTI earnings forecast
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, August, 4th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.01. The company had revenue of $39.68 million for the quarter, compared to the consensus estimate of $36.38 million.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $155.00 million-$165.00 million, compared to the consensus revenue estimate of $160.03 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $5.93.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $473.26 million and generates $209.82 million in revenue each year. The company earns $-124,090,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

The company employs 442 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.

This page (NASDAQ:KPTI) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.